With the U.S. government approving new guidelines for pre-clinical drug testing that promote the use of innovative technologies and approaches to minimize animal testing, this project couldn’t have come at a better time. The joint project between esqLABS, Dynamic42, Placenta Lab of Jena University Hospital, and Bayer’s Consumer Health Division is set to change the game by finding novel ways to minimize animal testing and generate reliable and accurate data for product safety and efficacy.

Dr. Christian Maass, OoC-Research Lead at esqLABS, said, “We are thrilled to collaborate with scientists from Dynamic42, the Placenta Lab, and Bayer’s Consumer Health Division through this joint project to find novel ways to minimize animal testing and at the same time seek to generate more reliable and accurate data for product’s safety and efficacy.” Dr. Stephan Schaller, CEO of esqLABS, added, “This is an unprecedented endeavour, and we are very excited to be part of this journey. We all share the same vision.”

This pilot project is a milestone in the development of new mechanisms for studying the placenta barrier and its bi-directional selective transport in humans. The combined strengths of esqLABS, Dynamic42, and Bayer, along with the Placenta Lab’s experience in the field, will work synergistically to offer a path from bench to bedside.